TCI Wealth Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

TCI Wealth Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$271K	Hold	517	–	–	0.01%	207
2025 Q4	$301K	Hold	517	–	–	0.02%	194
2025 Q3	$237K	Buy	+517	New	+$193K	0.01%	220
2023 Q2	–	Sell	-46	Closed	-$11.1K	–	1383
2023 Q1	$11.1K	Buy	+46	New	+$12.5K	﹤0.01%	1019
2022 Q2	–	Sell	-52	Closed	-$5K	–	2427
2022 Q1	$5K	Buy	+52	New	+$4.38K	﹤0.01%	1570
2021 Q2	–	Sell	-16	Closed	-$2K	–	2396
2021 Q1	$2K	Buy	+16	New	+$1.87K	﹤0.01%	1806
2019 Q4	–	Sell	-5	Closed	–	–	1628
2019 Q3	$0	Hold	5	–	–	﹤0.01%	1575
2019 Q2	$1K	Sell	5 -5	-50%	-$536	﹤0.01%	1245
2019 Q1	$1K	Hold	10	–	–	﹤0.01%	1258
2018 Q4	$1K	Buy	+10	New	+$1.55K	﹤0.01%	1258

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's MDGL Position: Q1 2026 in Review

TCI Wealth Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 517 shares worth $271K. The position accounts for 0.01% of the portfolio, ranked #207.

TCI Wealth Advisors first reported a position in MDGL in Q4 2018 and has held it in 10 quarters since. The position peaked at $301K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

TCI Wealth Advisors held 517 shares of Madrigal Pharmaceuticals worth $271K as of Q1 2026.
TCI Wealth Advisors left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
Madrigal Pharmaceuticals made up 0.01% of TCI Wealth Advisors's portfolio in Q1 2026, its #207 holding.
TCI Wealth Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2018 and has held it in 10 quarters since.
TCI Wealth Advisors's Madrigal Pharmaceuticals position peaked at $301K in Q4 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on TCI Wealth Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.